Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Insights - Medicus Pharma Ltd. shares experienced volatility, peaking at $1.61 before declining during premarket trading following the release of Phase 2 clinical trial data for SKNJCT-003 [1] - The Phase 2 study demonstrated a 73% clinical clearance rate for Doxorubicin Microneedle Array (D-MNA) in treating basal cell carcinoma (BCC), which may facilitate an end-of-phase meeting with the FDA in the first half of 2026 [2][3] Clinical Trial Results - The topline results from the SKNJCT-003 Phase 2 clinical study indicated a 73% clinical clearance rate and a 40% histological clearance rate from a 200µg dose cohort [3] - The study involved 90 patients diagnosed with nodular basal cell carcinoma, providing decision-grade evidence of clinical activity [3] Future Plans - The company plans to compile a comprehensive Clinical Study Report by the second quarter of 2026, which will include full safety analyses and procedural observations [4] Stock Performance - Medicus Pharma's stock is currently trading 8.70% above its 20-day simple moving average (SMA) but is 12.5% below its 100-day SMA, indicating short-term strength and longer-term challenges [5] - Over the past 12 months, shares have significantly decreased and are closer to their 52-week lows than highs, with the current price at $1.09 during premarket trading [5][7] Technical Analysis - The Relative Strength Index (RSI) is at 50.00, indicating neutral territory, while the MACD is at 0.10, below its signal line at 0.15, suggesting bearish pressure on the stock [6] - The combination of neutral RSI and bearish MACD indicates mixed momentum, prompting traders to monitor potential shifts in momentum [6]

Core Insights - Phio Pharmaceuticals Corp. announced positive results from its Phase 1b clinical trial for its lead candidate, PH-762, leading to a significant increase in share price [1] - The company has a market cap of $9 million and experienced a trading volume of 5.82 million, significantly higher than the average of 412.49 thousand [1] Safety Data Update - The Safety Monitoring Committee reported no serious adverse events or dose-limiting toxicities across all five dose escalation cohorts [2] - The highest dose concentration achieved an pathological response rate of 85%, with complete tumor clearance in four out of six responders [2] Treatment Details - A total of 22 patients with cutaneous carcinomas completed treatment, receiving 4 intratumoral injections of PH-762 [3] - The drug was evaluated in five dose-escalating cohorts, with a 20-fold increase in drug concentration from the first to the fifth cohort [3] Next Steps - An FDA submission for guidance on next steps in clinical study design for PH-762 is targeted for the second quarter of 2026 [4] - The company is on track to have material available for non-human primate studies by March 2026, which is necessary for commencing human pivotal trials [5] Technical Analysis - Phio Pharmaceuticals is currently trading 12.5% below its 20-day simple moving average (SMA) and 17.3% below its 50-day SMA, indicating a bearish trend [6] - Over the past 12 months, shares have decreased by approximately 49.44%, positioning the stock closer to its 52-week lows [6] Price Action - Phio Pharma shares were up 51.11% at $1.36 at the time of publication [8] - Key resistance level is at $1.00, while key support is at 81 cents [8]

Core Insights - Proactive provides fast, accessible, and actionable business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, mining, oil and gas, and emerging technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]